Navigation Links
Ovarian cancer patients have lower mortality rates when treated at high-volume hospitals

New York, NY (Nov. 8, 2012) A study by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork-Presbyterian/Columbia University Medical Center, recently e-published ahead of print by the Journal of Clinical Oncology, suggests that women who have surgery for ovarian cancer at high-volume hospitals have superior outcomes than similar patients at low-volume hospitals.

The improved survival rate is not dependent on a lower rate of complications following surgery, but on the treatment of the complications. In fact, patients with a complication after surgery at a low-volume hospital are nearly 50 percent more likely to die as a result of the complication than patients seen at high-volume hospitals.

"It is widely documented that surgical volume has an important effect on outcomes following surgery," said lead author Jason D. Wright, MD, the Levine Family Assistant Professor of Women's Health and the Florence Irving Assistant Professor of Obstetrics and Gynecology at CUMC, a gynecologic oncologist at NYP/Columbia, and a member of the HICCC.

"We examined three specific areas: the influence of hospital volume on complications, failure to rescue from complications, and inpatient mortality in ovarian cancer patients who underwent cancer-related surgery," said Dr. Wright. "But the mortality rate did not coincide with the complication rate. For women who experienced a complication at a low-volume hospital, the mortality rate was 8 percent. For women at a high-volume hospital, it was 4.9 percent. After adjusting for variables, we concluded that the failure-to-rescue rate was 48 percent higher at low-volume hospitals than at high-volume hospitals. In short, high-volume hospitals are better able to rescue patients with complications following ovarian cancer surgery."

The researchers used National Inpatient Sample data from 1998 to 2009, specifically, women aged 18 to 90 with ovarian cancer who under oophorectomy (removal of one or both ovaries): a total of more than 36,000 patients treated at 1,166 hospitals. After reviewing the data, the researchers noted several significant trends. For example, the complication rate increased with surgical volume: 20.4 percent for patients at low-volume hospitals, compared with 24.6 percent at high-volume hospitals.

Although the researchers could not account for all possible factors influencing these findingsthe NIS lacks data on physician characteristics and does not have data covering all US hospitals, for exampletheir findings have important implications for the care of patients with ovarian cancer.

"Our findings suggest that targeted initiatives to improve the care of patients with complications can improve outcomes," said Dawn L. Hershman, MD, associate professor of medicine and epidemiology at CUMC, an oncologist at NYP/Columbia, co-leader of the Breast Cancer Program at the HICCC, and a co-author of the study. "We also believe in the importance of adhering to quality guidelines and best practices, which may overcome these volume-based disparities.

"And at the most basic level, the findings highlight the importance of preventing complications to begin with. They increase mortality, in the worst-case scenario, but can also cause long-term medical problems, with patients and families facing difficult treatment choices and additional costs," said Dr. Hershman.


Contact: CUMC Communications
Columbia University Medical Center

Related medicine news :

1. Simple ovarian cancer symptom survey that checks for 6 warning signs may improve early detection
2. U.S. Panel Rejects Ovarian Cancer Screens for Low-Risk Women
3. Mechanisms of acquired chemoresistance in ovarian cancer identified
4. Benefit of PET and PET/CT in ovarian cancer is not proven
5. Ovarian Transplants May Preserve Fertility in Young Cancer Survivors
6. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
7. The prevention of hereditary breast and ovarian cancer by PGD is feasible
8. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
9. UC Irvine study finds racial, economic disparities in ovarian cancer care, survival
10. U.S. Panel Rejects Ovarian Cancer Screening
11. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
Post Your Comments:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... certified to offer their patients the many benefits of the revolutionary BIOLASE WaterLase ... sharp cutting and scraping tools traditionally used by a dentist in Gettysburg, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... their Black Friday sale a week early, offering 40% off select bras and ... intimate apparel industry through both mobile fit technology and the latest fashion, quickly ...
(Date:11/24/2015)... ... ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, Dec. ... has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls under ... the device regulations. , Come up short in an inspection and the FDA can ...
(Date:11/24/2015)... ... November 24, 2015 , ... United Benefit Advisors (UBA), the ... Company as its newest Partner Firm. Based in Jefferson City, Missouri, their core ... advisor regardless of whether that client is a business, a family, or an ...
(Date:11/24/2015)... LINCOLN, R.I. (PRWEB) , ... November 24, 2015 , ... ... why Amica Insurance is sharing safety tips to help protect your family and vehicle. ... traffic crashes around the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Trovagene, Inc. ... diagnostics, today announced that Chief Executive Officer Antonius Schuh, ... the 27 th Annual Piper Jaffray Healthcare Conference. ... at the New York Palace Hotel in ... at 1:30 p.m. EST. Mr. Schuh will be available ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Today AVACEN Medical announced the issue of ... Thermal Energy Including Blood Viscosity Adjustment ". This patent shields the company,s AVACEN 100 dry heat ... Treatment Method. Photo - ... ... ...
(Date:11/25/2015)... 2015 Allergan plc (NYSE: AGN ... Therapeutics, a start-up  biotechnology company focused on the ... and funded by the F-Prime Biomedical Research Initiative ... an exclusive collaboration to support the discovery and ... (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: